VCEL
$32.50
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Intraday
Recent News
What Makes Vericel Corporation (VCEL) an Investment Bet?
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Small Cap Fund”. A copy of the letter can be downloaded here. The fourth quarter was challenging for the fund and continued to underperform its benchmark, the Russell 2000 Index. The fund (Class I) returned -0.4%, lagging the benchmark’s 2.2% return. Sector allocation […]
Will FDA Approval of Burlington MACI Manufacturing Shift Vericel's (VCEL) Long-Term Growth Narrative
In early March 2026, Vericel Corporation reported that the FDA approved commercial manufacturing of its knee cartilage repair therapy MACI at the company’s Burlington, Massachusetts cell therapy facility, allowing production to begin there in the second quarter of 2026. This manufacturing approval not only expands MACI capacity and strengthens Vericel’s supply chain, but also underpins the company’s ability to pursue international commercialization of its autologous cell therapy...
FDA MACI Approval Tests Vericel’s Capacity Plans And Growth Story
Vericel received FDA approval for commercial manufacturing of MACI at its new Burlington facility. The approval allows expanded production capacity for the company’s cartilage repair therapy. The new site is expected to support Vericel’s plans for potential MACI commercialization outside the U.S. For investors watching Vericel, ticker NasdaqGM:VCEL, this FDA decision marks an important operational shift as the company looks to support demand for MACI. The stock last closed at $34.12, with a...
Vericel Corporation (VCEL) Secures FDA Approval for Commercial Manufacturing of MACI
Vericel Corporation (NASDAQ:VCEL) is one of the Best Small-Cap Growth Stocks to Buy According to Hedge Funds. On March 4, Vericel Corporation (NASDAQ:VCEL) announced securing a major win from the FDA. The company announced receiving FDA approval for commercial manufacturing of MACI, which is the company’s autologous cultured chondrocytes on a porcine collagen membrane. The […]
MediWound Updates NexoBrid Growth, EscharEx Phase III Timeline and BARDA Talks at Oppenheimer Conference
MediWound (NASDAQ:MDWD) CEO Ofer Gonen provided an update on the company’s commercial burn franchise, late-stage chronic wound program, manufacturing expansion plans, and government-related efforts during Oppenheimer’s Annual Healthcare Conference. Company overview: commercial burns product and lat